US FDA shows flexibility on unapproved opioids ban
This article was originally published in SRA
The US Food and Drug Administration, as it moves ahead with its initiative to ensure that all drugs available on the market meet required standards for safety and efficacy, has temporarily allowed seven companies to continue the marketing and distribution of an unapproved opioid drug1. The drug in question is a high-concentrate morphine sulfate oral solution that is widely used to alleviate pain in terminally ill patients.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.